131I-cG250

N/A

Report date: 2025/09/15 20:01:49

NME

Base Information

Drug Name131I-cG250

Drug Alias NameIodine-131 radiolabeled chimeric monoclonal antibody G250131I-cG250

ClassificationRadiation-emitting products > Nuclides > Iodine > 131IRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-Carbonic anhydrase IX

TargetsCarbonic anhydrase IX

Therapy Area/IndicationsKidney Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesLudwig Institute For Cancer Research National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLudwig Institute For Cancer Research National Cancer Institute

Active IndicationsN/A

Inactive IndicationsKidney Neoplasms

Other Information

ATC CodeN/A